TOPCHOICE MEDICAL CORPORATION plans to repurchase and cancel shares worth 50 million to 100 million yuan, following the disclosure of share purchase plans by five senior executives.

Source: Topchoice Medical's Announcement on Share Repurchase Plan via Centralized Competitive Bidding

DentalGoodNews｜On June 4, 2026, TOPCHOICE MEDICAL CORPORATION (hereinafter referred to as "TOPCHOICE MEDICAL") issued an announcement stating that it plans to repurchase its own shares through centralized auction trading using its own funds or self-raised funds, with a repurchase amount ranging from RMB 50 million to RMB 100 million. The repurchased shares will all be used to reduce the company's registered capital (cancellation of shares), with the repurchase price cap set at RMB 60.12 per share.

According to the announcement, the repurchase period is 12 months from the date of approval by the shareholders' meeting. Based on the repurchase price cap, the estimated number of shares to be repurchased ranges from 831,670 to 1,663,339 shares, accounting for approximately 0.04% to 0.08% of the company's current total share capital. TOPCHOICE MEDICAL stated that this move is based on confidence in the company's future development prospects and recognition of its intrinsic value, aiming to safeguard Shareholders' Equity and optimize the equity structure.

According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), in February 2026, five senior executives of TOPCHOICE MEDICAL, including Chairman Wang Yi and Director Huang Yuhua, disclosed a share increase plan with an expected total increase amount ranging from RMB 6 million to RMB 12 million, and completed the first share increase of RMB 1.8161 million on February 13. This announcement confirms that the company's controlling shareholder, actual controller, directors, supervisors, and senior management have no plans to reduce their holdings in the next 3 to 6 months.

In terms of financial data, as of March 31, 2026, TOPCHOICE MEDICAL's total assets were RMB 6.239 billion, net assets attributable to shareholders of the listed company were RMB 4.421 billion, and book monetary funds were RMB 792 million. Based on the lower limit of the repurchase fund of RMB 50 million, the repurchase amount accounts for approximately 0.80% of its total assets and 1.13% of its net assets. TOPCHOICE MEDICAL stated that the company currently has sufficient funds, and the repurchase plan will not have a significant impact on daily operations, research and development, or debt repayment capabilities.

Regarding the review process, on June 3, 2026, the company held the 14th meeting of the 10th Board of Directors and unanimously approved the plan. According to relevant regulations, TOPCHOICE MEDICAL must promptly notify creditors after the shareholders' meeting makes a resolution, and creditors have the right to request the company to repay debts or provide corresponding guarantees. Independent directors believe that this repurchase is compliant, necessary, and feasible, and there is no situation that would harm the interests of minority shareholders.

As of now, the repurchase plan still needs to be submitted to the company's shareholders' meeting for approval.